Afrigen Biologics
Cape Town, South Africa· Est.
South African biotech delivering affordable vaccines and biosimilars using proprietary biologics platforms.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $120M
AI Company Overview
South African biotech delivering affordable vaccines and biosimilars using proprietary biologics platforms.
Infectious DiseasesOncologyImmunology
Technology Platform
Proprietary high‑density cell‑culture and modular protein‑expression platform enabling rapid development of recombinant vaccines, monoclonal antibodies, and biosimilars.
Opportunities
Rapidly expanding African demand for affordable biologics and vaccines, plus potential export of biosimilars to emerging markets.
Risk Factors
Regulatory approvals in multiple jurisdictions, competition from established global biosimilar manufacturers, and reliance on continued government funding.
Competitive Landscape
Competes with global biosimilar leaders such as Sandoz, Biocon, and Mylan, differentiating through local manufacturing capacity and cost‑effective production for African markets.